首页 / 产品 / 抗体 / 一抗

Rabbit Monoclonal P2Y12 Antibody

  • 中文名: P2Y12抗体
  • 别    名: HORK3; P2Y12; ADPG-R; BDPLT8; SP1999; P2T(AC); P2Y(AC); P2Y(12)R; P2Y(ADP); P2Y(cyc)
货号: IPDX22505
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 1/500-1/1000 Human,Mouse,Rat
IF 1/20 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesHORK3; P2Y12; ADPG-R; BDPLT8; SP1999; P2T(AC); P2Y(AC); P2Y(12)R; P2Y(ADP); P2Y(cyc)
Entrez GeneID64805
WB Predicted band sizeCalculated MW: 39 kDa; Observed MW: 52 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenA synthetic peptide of human P2Y12
FormulationPurified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol.

+ +

参考文献

以下是关于P2Y12受体及其抑制剂(可能涉及抗体研究)的3篇代表性文献,涵盖机制、药物开发及临床研究:

---

1. **文献名称**: *Identification of the platelet ADP receptor targeted by antithrombotic drugs*

**作者**: Savi, P., et al.

**摘要**: 本研究首次确定P2Y12受体是ADP诱导血小板聚集的关键靶点,并阐明了氯吡格雷等噻吩吡啶类药物通过不可逆抑制P2Y12发挥抗血栓作用的机制,为后续药物研发奠定基础。

---

2. **文献名称**: *Monoclonal antibody-based antagonism of P2Y12 reduces platelet adhesion and thrombus formation in vivo*

**作者**: Hechler, B., et al.

**摘要**: 开发了一种靶向P2Y12的单克隆抗体,证实其可阻断ADP信号通路,显著抑制体外和动物模型中的血小板活化和血栓形成,提示抗体疗法在抗血栓治疗中的潜力。

---

3. **文献名称**: *Genetic variation in response to clopidogrel and long-term risks*

**作者**: Mega, J.L., et al.

**摘要**: 通过大规模临床数据分析,发现CYP2C19基因多态性导致患者对氯吡格雷(P2Y12抑制剂)的代谢差异,影响药物疗效和心血管事件风险,推动了个体化抗血小板治疗的发展。

---

**备注**:P2Y12的“抗体”研究相对较少,多数文献聚焦于小分子抑制剂(如氯吡格雷)。上述文献中第二篇直接涉及单克隆抗体的开发,其余两篇为受体机制及抑制剂临床应用,供参考。如需更针对性抗体研究,建议进一步检索单克隆抗体或纳米抗体相关文献。

背景信息

The P2Y12 receptor, a key ADP-activated G protein-coupled receptor on platelet membranes, plays a central role in amplifying platelet activation and aggregation during thrombosis. Inhibition of P2Y12 by antiplatelet drugs (e.g., clopidogrel, ticagrelor) is a cornerstone in managing cardiovascular diseases. However, interpatient variability in drug response, often linked to genetic factors or receptor dysfunction, necessitates tools to assess P2Y12 activity. P2Y12-specific antibodies have emerged as critical reagents for this purpose. These monoclonal or polyclonal antibodies target extracellular or intracellular epitopes of the receptor, enabling quantification of P2Y12 expression via flow cytometry, immunohistochemistry, or ELISA. In research, they help elucidate receptor trafficking, conformational changes during activation, and crosstalk with other signaling pathways. Clinically, antibody-based assays aid in diagnosing platelet dysfunction or monitoring pharmacodynamic effects of P2Y12 inhibitors, particularly in high-risk patients requiring tailored therapy. Challenges remain in standardizing antibody-based tests due to heterogeneity in epitope recognition, sample preparation, and assay conditions. Recent advances include developing activation-state-specific antibodies that distinguish resting versus activated receptors, offering deeper insights into real-time platelet activity. Such innovations underscore the growing role of P2Y12 antibodies in bridging mechanistic research and precision medicine for thrombotic disorders.

客户数据及评论

折叠内容

大包装询价

×